India's Serum Institute will supply 1.1 billion doses of COVID-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme as part of a new long-term deal, head of the U.N. Children's Fund said on Wednesday.
UNICEF chief Henrietta Fore said the shots would be delivered over a number of years at the cost of about $3 per dose for low- and middle-income countries.
They would be produced by Serum under a technology transfer agreement, she said in a briefing.
The COVAX facility is co-led by GAVI, the World Health Organization, the Coalition for Epidemic Preparedness Innovations and UNICEF.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU